ABD - İngilizce - NLM (National Library of Medicine)

glaxosmithkline llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i), tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - dutasteride 0.5 mg - jalyn (dutasteride and tamsulosin hydrochloride) capsules are indicated for the treatment of symptomatic bph in men with an enlarged prostate. dutasteride-containing products, including jalyn, are not approved for the prevention of prostate cancer. jalyn is contraindicated for use in: •   pregnancy. dutasteride use is contraindicated in females who are pregnant. in animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. therefore, jalyn may cause fetal harm when administered to a pregnant female [see warnings and precautions ( 5.6), use in specific populations ( 8.1)] . •   patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema, urticaria, pruritus, respiratory symptoms) to dutasteride, other 5-alpha-reductase inhibitors, tamsulosin, or any other component of jalyn [see adverse reactions (6.2) ] . risk summary jalyn is contraindicated for use in pregnancy because it may cause

ABD - İngilizce - NLM (National Library of Medicine)

glaxosmithkline llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

ABD - İngilizce - NLM (National Library of Medicine)

a-s medication solutions - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: - improve symptoms, - reduce the risk of acute urinary retention (aur), and - reduce the risk of the need for bph-related surgery. dutasteride capsules in combination with the alpha adrenergic antagonist, tamsulosin, are indicated for the treatment of symptomatic bph in men with an enlarged prostate. dutasteride capsules are not approved for the prevention of prostate cancer. dutasteride, usp is contraindicated for use in: - pregnancy. in animal reproduction and developmental toxicity studies, dutasteride, usp inhibited development of male fetus external genitalia. therefore, dutasteride, usp may cause fetal harm when administered to a pregnant woman. if dutasteride, usp is used during pregnancy or if the patient becomes pregnant while taking dutasteride, usp, the patient should be apprised of the potential hazard to the fetus [see warnings and precautions (5.4), use in s

ABD - İngilizce - NLM (National Library of Medicine)

lake erie medical & surgcial supply dba quality care products llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg

ABD - İngilizce - NLM (National Library of Medicine)

avera mckennan hospital - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg

ABD - İngilizce - NLM (National Library of Medicine)

glaxosmithkline llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) -

ABD - İngilizce - NLM (National Library of Medicine)

woodward pharma services llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

ABD - İngilizce - NLM (National Library of Medicine)

waylis therapeutics llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

Fransa - Fransızca - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

biogaran - dutastéride 0; tamsulosine 0 - gélule - 0,5 mg - pour une gélule > dutastéride 0,5 mg > tamsulosine 0,367 mg sous forme de : chlorhydrate de tamsulosine 0,4 mg - antagonistes des récepteurs adrénergiques alpha - dutasteride/tamsulosine biogaran est utilisé dans le traitement de l'hypertrophie bénigne de la prostate (augmentation du volume de la prostate) chez les hommes. c'est un grossissement non cancéreux de la glande prostatique, provoqué par la production trop importante d'une hormone appelée dihydrotestostérone.dutasteride/tamsulosine biogaran est une association de deux médicaments différents : le dutastéride et la tamsulosine.le dutastéride appartient à un groupe de médicaments appelé les inhibiteurs de la 5-alpha-réductase et la tamsulosine appartient à un groupe de médicaments appelé les alpha-bloquants.l'augmentation du volume de la prostate peut provoquer des problèmes urinaires, tels que des difficultés pour commencer à uriner et une envie fréquente d'uriner. le jet d'urine peut également être ralenti et moins puissant. si elle n'est pas traitée, il y a un risque que votre écoulement urinaire soit complètement bloqué (rétention aiguë d'urine). ceci nécessite un traitement médical immédiat. dans certains cas, le recours à la chirurgie est nécessaire pour enlever ou réduire la taille de la glande prostatique.le dutastéride diminue la production de dihydrotestostérone, ce qui permet de réduire la taille de la prostate et d'améliorer les symptômes. ceci réduit le risque de rétention aiguë d'urine et le recours à la chirurgie. la tamsulosine agit en relâchant les muscles de votre prostate, facilitant ainsi la miction et améliorant rapidement vos symptômes.

Fransa - Fransızca - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

zentiva france - dutastéride 0 - capsule - 0,5 mg - pour une capsule > dutastéride 0,5 mg - inhibiteurs de la 5-alpha-testosterone reductase - dutasteride zentiva lab est utilisé dans le traitement de l’augmentation du volume de la prostate (hypertrophie bénigne de la prostate) chez les hommes. il s’agit d’un grossissement non cancéreux de la glande prostatique, provoqué par la production trop importante d'une hormone appelée dihydrotestostérone.la substance active contenue dans ce médicament est le dutastéride. il appartient à un groupe de médicaments appelés inhibiteurs de la 5-alpha réductase.l'augmentation du volume de la prostate peut provoquer des problèmes urinaires, tels que des difficultés à uriner et une envie fréquente d'uriner. le jet d'urine peut également être ralenti et moins puissant. si cette affection n'est pas traitée, il y a un risque que votre écoulement urinaire soit complètement bloqué (rétention aiguë d'urine). ceci nécessite un traitement médical immédiat. dans certains cas, le recours à la chirurgie est nécessaire pour enlever ou réduire la taille de la glande prostatique. dutasteride zentiva lab diminue la production de dihydrotestostérone, ce qui permet de réduire la taille de la prostate et de soulager les symptômes. cela permet de réduire le risque de rétention aiguë d'urine et le recours à la chirurgie.dutasteride zentiva lab peut également être utilisé avec un autre médicament appelé tamsulosine (utilisé pour traiter les symptômes de l’hypertrophie de la prostate).